SL-701

· Stemline Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SL-701, covering 2023-12-06 to 2023-12-06. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme [Phase 1, Phase 2]

See pricing